Showing results (21-30 of 39) with videos related to
Sort By:
Pageof 4
Oncotarget|October 8, 2016
A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumorsAndrew D J Pearson, Sara M Federico, Isabelle Aerts, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2013
A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumorsLia Gore, Tanya M Trippett, Howard M Katzenstein, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 21, 2005
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901John D Roberts, Donna Niedzwiecki, William E Carson, et al.Cancer Chemotherapy and Pharmacology|April 24, 2013
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignanciesDaryl Sonnichsen, David J Dorer, Jorge Cortes, et al.The New England Journal of Medicine|May 1, 2004
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibThomas J Lynch, Daphne W Bell, Raffaella Sordella, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology GroupLawrence E Flaherty, Megan Othus, Michael B Atkins, et al.The Lancet. Oncology|November 13, 2016
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trialScott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomasSant P Chawla, Arthur P Staddon, Laurence H Baker, et al.The New England Journal of Medicine|November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemiasJorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunityGerald P Linette, Dongsheng Zhang, F Stephen Hodi, et al.Pageof 4